Paladin Labs Company Profile (TSE:PLB)

About Paladin Labs (TSE:PLB)

Paladin Labs logoPaladin Labs Inc. is a specialty pharmaceutical company focused on developing, acquiring, in-licensing, marketing and distributing pharmaceutical products. The Company's product portfolio includes Tridural, Abstral and Trelstar. Tridural is a once-a-day tramadol product indicated as a first-line therapy for adults with moderate pain requiring several days or more of treatment. Abstral is a sublingual tablet used for the management of breakthrough cancer pain in patients who are already tolerant to other opioid analgesics. Trelstar is an injectable, luteinizing hormone releasing hormone agonist indicated for the palliative treatment of prostate cancer and endometriosis. In July 2013, the Company became the sole holder of Allon Therapeutics Inc. In September 2013, Blackstar Group SE announced that it has sold remaining 13.4% interests in Litha Healthcare Group Limited (Litha) to Paladin Labs Inc. Effective January 1, 2014, Paladin Labs Inc. acquired Triton Pharma Inc.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: TSE:PLB
  • CUSIP: N/A
  • Web: N/A
  • Trailing P/E Ratio:
  • P/E Growth:
  • Dividend Yield: 1.0%
Frequently Asked Questions for Paladin Labs (TSE:PLB)

What is Paladin Labs' stock symbol?

Paladin Labs trades on the Tornton Stock Exchange (TSX) under the ticker symbol "PLB."

Who are some of Paladin Labs' key competitors?

How do I buy Paladin Labs stock?

Shares of Paladin Labs and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Paladin Labs' stock price today?

One share of Paladin Labs stock can currently be purchased for approximately C$142.06.

MarketBeat Community Rating for Paladin Labs (TSE PLB)
Community Ranking:  1.4 out of 5 ()
Outperform Votes:  17 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  62
MarketBeat's community ratings are surveys of what our community members think about Paladin Labs and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Paladin Labs (TSE:PLB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Paladin Labs (TSE:PLB)
No equities research coverage for this company has been tracked by


Earnings History for Paladin Labs (TSE:PLB)
Earnings by Quarter for Paladin Labs (TSE:PLB)
Earnings History by Quarter for Paladin Labs (TSE PLB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2013Q3$0.66$0.61ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Paladin Labs (TSE:PLB)
Current Year EPS Consensus Estimate: $0.00 EPS
Next Year EPS Consensus Estimate: $0.00 EPS


Dividend History for Paladin Labs (TSE:PLB)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Paladin Labs (TSE:PLB)
No insider trades for this company have been tracked by


Headline Trends for Paladin Labs (TSE:PLB)
Latest Headlines for Paladin Labs (TSE:PLB)



Paladin Labs (PLB) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff